Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice

Growth Factors

Volumn 33, Issue 5-6, 2015, Pages 366-375

  Yilmaz, Oznur ^a   Oztay, Fusun ^a   Kayalar, Ozgecan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

C Abl; Dasatinib; ERK1 2; Fibroblasts; PDGFR ; Pulmonary fibrosis

Indexed keywords

ABELSON KINASE; ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; BLEOMYCIN; COLLAGEN TYPE 1; DASATINIB; KI 67 ANTIGEN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; ANTINEOPLASTIC ANTIBIOTIC; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CELL ACTIVATION; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; IMMUNOREACTIVITY; INFLAMMATORY CELL; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA ISOLATION; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; LUNG; METABOLISM; PATHOLOGY; PULMONARY FIBROSIS;

ACTINS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CELL PROLIFERATION; COLLAGEN TYPE I; DASATINIB; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; LUNG; MALE; MICE; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PULMONARY FIBROSIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SRC-FAMILY KINASES;

EID: 84955183318     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2015.1109511     Document Type: Article

References (57)

1. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, et al. 2005. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201:925-935.
2. Adachi K, Mizoguchi K, Kawarada S, Miyoshi A, Suzuki M, Chiba S, Deki T. 2010. Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. J Toxicol Sci 35:503-514.
3. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, Zwerina J, et al. 2008. Dual inhibition of c-Abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 22:2214-2222.
4. Andrae J, Galini R, Betsholtz C. 2008. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276-1312.
5. Antoniou KM, Margaritopoulos GA, Soufla G, Symvoulakis E, Vassalou E, Lymbouridou R, Samara KD, et al. 2010. Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). J Recep Signal Transduct Res 30: 262-269.
6. Antoniu SA. 2012. Nintedanib (BIBF 1120) for IPF: A tomorrow therapy? Multidiscip Respir Med 7:41-51.
7. Azuma M, Nishioka Y, Aono Y, Inayama M, Makino H, Kishi J, Shono M, et al. 2007. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med 176:1243-1250.
8. Barber NA, Ganti AK. 2011. Pulmonary toxicities from targeted therapies: A review. Target Oncol 6:235-243.
9. Bikfalvi A. 2004. Recent developments in the inhibition of angiogenesis: Examples from studies on platelet factor-4 and the VEGF/VEGFR system. Biochem Pharmacol 68:1017-1021.
10. Bonner JC, Lindroos PM, Rice AB, Moomaw CR, Morgan DL. 1998. Induction of PDGF receptor-alpha in rat myofibroblasts during pulmonary fibrogenesis in vivo. Am J Physiol 274:72-80.
11. Bonner JC. 2004. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15:255-273.
12. Bonner JC. 2010. Mesenchymal cell survival in airway and interstitial pulmonary fibrosis. Fibrogenesis Tissue Repair 3:15-51.
13. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE. 2007. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 29:976-985.
14. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. 2004. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114:1308-1316.
15. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR. 2010. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 181:604-610.
16. Donovan J, Shiwen X, Norman J, Abraham D. 2013. Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts. Fibrogenesis Tissue Repair 6:10.
17. Galuppo M, Esposito E, Mazzon E, Di Paola R, Paterniti I, Impellizzeri D, Cuzzocrea S. 2011. MEK inhibition suppresses the development of lung fibrosis in the bleomycin model. Naunyn Schmiedebergs Arch Pharmacol 384:21-37.
18. Haubeiss S, Schmid JO, Murdter TE, Sonnenberg M, Friedel G, van der Kuip H, Aulitzky WE. 2010. Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer 9:168-183.
19. Hubner RH, Gitter W, Mokhtari NE, Mathiak M, Both M, Bolte H, Freitag-Wolf S, Bewig B. 2008. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 44: 507-511.
20. Hu M, Che P, Han X, Cai GQ, Liu G, Antony V, Luckhardt T, et al. 2014. Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis. J Pharmacol Exp Ther 351:87-95.
21. Hu Y, Peng J, Feng D, Chu L, Li X, Jin Z, Lin Z, Zeng Q. 2006. Role of extracellular signal-regulated kinase, p38 kinase, and activator protein-1 in transforming growth factor-beta1-induced alpha smooth muscle actin expression in human fetal lung fibroblasts in vitro. Lung 184:33-42.
22. Ishii Y, Fujimoto S, Fukuda T. 2006. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med 174: 550-556.
23. Johnson FM, Saigal B, Talpaz M, Donato NJ. 2005. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11: 6924-6932.
24. Kayalar O, Oztay F. 2014. Retinoic acid induced repair in the lung of adult hyperoxic mice, reducing transforming growth factor-b1 (TGF-b1) mediated abnormal alterations. Acta Histochem 116:810-819.
25. Kis K, Liu X, Hagood JS. 2011. Myofibroblast differentiation and survival in fibrotic disease. Expert Rev Mol Med 13:1-24.
26. Konigshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, Rose F, et al. 2009. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 119:772-787.
27. Lasky JA, Tonthat B, Liu JY, Friedman M, Brody AR. 1998. Upregulation of the PDGF-alpha receptor precedes asbestos-induced lung fibrosis in rats. Am J Respir Crit Care Med 157:1652-1657.
28. Lipson KE, Pang L, Huber LJ, Chen H, Tsai JM, Hirth P, Gazit A, et al. 1998. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. J Pharmacol Exp Ther 285:844-852.
29. Matsuoka H, Arai T, Mori M, Goya S, Kida H, Morishita H, Fujiwara H, et al. 2002. A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 283:103-112.
30. Montero JC, Seoane S, Ocana A, Pandiella A. 2011. Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors. Clin Cancer Res 17:5546-5552.
31. Murray LA, Argentieri RL, Farrell FX, Bracht M, Sheng H, Whitaker B, Beck H, et al. 2008. Hyper-responsiveness of IPF/UIP fibroblasts: Interplay between TGF-beta1, IL-13 and CCL2. Int J Biochem Cell Biol 40:2174-2182.
32. Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, Zhang SF, et al. 2009. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int Immunopharmacol 9:70-79.
33. Ovet H, Oztay F. 2014. The copper chelator tetrathiomolybdate regressed bleomycin-induced pulmonary fibrosis in mice, by reducing of lysyl oxidase expressions. Biol Trace Elem Res 162:189-199.
34. Oztay F, Yilmaz O. 2015. Method of treating fibrotic diseases using dasatinib. TR201503969A2.
35. Oztay F, Gezginci-Oktayoglu S, Bayrak B, Yanardag R, Bolkent S. 2010. Cathepsin B inhibition improves lung injury associated to D-galactosamine/tumor necrosis factor-alpha-induced liver injury in mice. Mol Cell Biochem 333:65-72.
36. Oztay F, Sacan O, Kayalar O, Bolkent S, Ipci Y, Kabasakal L, Sener G, Yanardag R. 2015. Chard (Beta vulgaris var. cicla) extract improved hyperglycemia-induced oxidative stress and surfactant-associated protein alterations in rat lungs. Pharm Biol 53:1639-1646.
37. Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM. 1999. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 13:2400-2411.
38. Rice AB, Moomaw CR, Morgan DL, Bonner JC. 1999. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 155:213-221.
39. Richeldi L, Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. 2011. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079-1087.
40. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, et al. 2014. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071-2082.
41. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X, Breitman ML, Schuh AC. 1995. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature 376:62-66.
42. Sirvent A, Benistant C, Roche S. 2008. Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell 100: 617-631.
43. Suzuki H, Aoshiba K, Yokohori N, Nagai A. 2003. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 63:5054-5059.
44. Swords R, Maralinga D, Padmanabhan S, Carew J, Giles F. 2009. Nilotinib: Optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 3: 89-101.
45. Trojanowska M. 2008. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 47:2-4.
46. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, et al. 2000. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 279: 895-902.
47. Vittal R, Horowitz JC, Moore BB, Zhang H, Martinez FJ, Toews GB, Standiford TJ, Thannickal VJ. 2005. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am J Pathol 166:367-375.
48. Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ. 2007. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: Implications for treatment of fibrotic diseases. J Pharmacol Exp Ther 321:35-44.
49. Wang S, Wilkes MC, Leof EB, Hirschberg R. 2005. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 19:1-11.
50. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL. 2001. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 98:4622-4627.
51. White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, Mak TW, Hoqaboam CM, et al. 2006. Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10). Am J Respir Crit Care Med 173:112-121.
52. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. 2014. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349:209-220.
53. Wynn TA. 2008. Cellular and molecular mechanisms of fibrosis. J Pathol 214:199-210.
54. Wynn TA. 2011. Integrating mechanisms of pulmonary fibrosis. J Exp Med 208:1339-1350.
55. Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, et al. 2005. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 288:907-913.
56. Zhang K, Rekhter MD, Gordon D, Phan SH. 1994. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am J Pathol 145:114-125.
57. Zhu B, Ma AQ, Yang L, Dang XM. 2013. Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway. Int J Mol Sci 14: 24476-24491.